Ed Kaye is taking his fledgling biotech to Wall Street, looking for a new injection of cash
Ed Kaye should soon be back to running a public biotech.
The Stoke Therapeutics CEO, who cut short a brief break after his exit from Sarepta to run the fledgling startup and unveil a lean $40 million launch round primarily from Apple Tree Partners, has steered an S-1 to the SEC. And he’s penciled in a $86 million raise, looking for Wall Street to fund their last steps through preclinical work on a lead program.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.